Regulators finalized a rule Wednesday that would slash payments for drugs in the controversial 340B program and equalize some ...
The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of ...
AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...
J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment ...
The occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into ...
The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier ...
Wall Street analysts are already resetting projections for Rasonque — but company executives cautioned that it’s too early to ...
Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have ...
On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall ...
The FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy. Elsewhere, a biotech’s share price was cut in half following a regulatory setback.
The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a ...
The startup is built around technology it claims can help get after known, but undruggable cancer targets and design ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results